Pent(r)axin 3, which we found to be up-regulated in MVECs of SSc patients, inhibits the pro-angiogenic effect of Fibroblast Growth Factor-2 (FGF2), including that produced by autocriny of endothelial cells [14]. The gene discussed is FGF2; the disease is systemic sclerosis.